



## Post Authorisation Assessments

### Orbenin L.A. 200 mg Intramammary Suspension Vm 42058/4090

<ul style="list-style-type: none"> <li>02 May 2023</li> </ul>	<p>Change in the specification parameters or limits of the finished product to describe more accurately the appearance of the product.</p> <p>Change in the specification parameters or limits of the finished product: – addition of a new specification parameter to the specification with its corresponding test method.</p> <p>Change in the specification parameters or limits of the finished product: – addition of a new specification parameter to the specification with its corresponding test method.</p> <p>Change in the specification parameters or limits of the finished product: – tightening of specification limits.</p>
<ul style="list-style-type: none"> <li>28 April 2023</li> </ul>	<p>Change in test procedure for the finished product: - Other changes to a test procedure (including replacement or addition).</p> <p>Change in test procedure for the finished product: - Other changes to a test procedure (including replacement or addition).</p> <p>Change in test procedure for the finished product: - Other changes to a test procedure (including replacement or addition).</p> <p>Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product: - Minor change in the manufacturing process.</p> <p>Change in the specification parameters and/or limits of the finished product: - Other changes.</p> <p>Change in the specification parameters and/or limits of the finished product: - Other changes.</p> <p>Change in the batch size (including batch size ranges) of the finished product: - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes.</p>
<ul style="list-style-type: none"> <li>29 March 2023</li> </ul>	<p>Change in specification parameters and/or limits of a measuring or administration device: - Other changes.</p>
<ul style="list-style-type: none"> <li>09 December 2020</li> </ul>	<p>Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer.</p>
<ul style="list-style-type: none"> <li>04 September 2020</li> </ul>	<p>Change in the address of the marketing authorisation holder from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive,</p>

		Leatherhead, Surrey, KT22 7LP.
•	05 August 2020	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
•	11 April 2017	Change of specification of a former non Pharmacopoeial excipient starting material to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State
•	10 September 2015	Change to withdrawal period from 84 hours to 96 hours.
•	26 June 2014	Change to the Marketing Authorisation Holder and distributor details.
•	23 July 2009	Change in the name of the manufacturer of the finished product.
•	03 October 2007	Change in the SPC and product literature to bring into line with new legislation. Change of legal category from POM to POM-V.
•	22 June 2006	Change in the manufacturing process of the active substance.
•	26 January 2006	Renewal.
•	15 July 2005	Change of distributor.
•	07 January 2005	Change of name of manufacturer of active substance.
•	18 November 2004	Renewal.
•	16 January 2004	Change in the product container shape.
•	27 February 2003	Change in the name of an assembler of the finished product.
•	15 March 2002	Change to comply with Pharmacopoeia.
•	08 December 2000	Change in manufacturer of the active substance.
•	03 November 1997	Renewal.